Cell Therapy News

A novel anti-CD30 chimeric antigen receptor T-cell therapy conferred a high rate of durable responses among patients with heavily pretreated Hodgkin lymphoma who underwent fludarabine-based lymphodepletion, according to study results.

Tisagenlecleucel conferred clinically meaningful benefit to patients with relapsed or refractory follicular lymphoma, according to topline results of the phase 2 ELARA trial released by the agent’s manufacturer.

Parker Institute for Cancer Immunotherapy appointed John Connolly, PhD, as its chief scientific officer.

Bristol-Myers Squibb and bluebird bio resubmitted a biologics license application to the FDA for idecabtagene vicleucel — an investigational chimeric antigen receptor T-cell therapy — for the treatment of adults with relapsed or refractory multiple myeloma.

The FDA cleared an investigational new drug application for CT-0508 for the treatment of solid tumors that overexpress HER2, according to a press release from the agent’s manufacturer.

ICTCAR014 — a novel chimeric antigen receptor T-cell therapy “armored” with a dominant-negative PD-1 molecule — induced high response rates among patients with relapsed or refractory B-cell non-Hodgkin lymphoma, study results showed.

The FDA granted accelerated approval to brexucabtagene autoleucel for treatment of adults with relapsed or refractory mantle cell lymphoma.

The development of chimeric antigen receptor T-cell therapy has revolutionized treatment for patients with advanced blood cancers.

A gamma-delta T-cell therapy failed to significantly prolong PFS for patients with treatment-refractory non-small cell lung cancer, according to study results presented at American Association for Cancer Research Virtual Annual Meeting II.

Switching a B-cell lymphoma or leukemia treatment from CD20-directed immunotherapy to an alternative option may offer a successful alternative to desensitization protocols in instances of severe drug hypersensitivity.